Abstract:Objective: This review aimed to assess the current use and acceptance of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) process. It additionally aimed to discern stakeholders’ viewpoints concerning RWD and RWE in HTA and illuminate the obstacles, difficulties, prospects, and consequences associated with the incorporation of RWD and RWE into the realm of HTA. Methods: A comprehensive PRISMA-based systematic review was performed in July 2022 in PubMed/Medline, Scopus, IDEAS-RePEc, International HTA database, and Centre for Reviews and Dissemination with ad hoc supplementary search in Google Scholar and international organization websites. The review included pre-determined inclusion criteria while the selection of eligible studies, the data extraction process and quality assessment were carried out using standardized and transparent methods. Results: Twenty-nine ( n = 29) studies were included in the review out of 2,115 studies identified by the search strategy. In various global contexts, disparities in RWD utilization were evident, with randomized controlled trials (RCTs) serving as the primary evidence source. RWD and RWE played pivotal roles, surpassing relative effectiveness assessments (REAs) and significantly influencing decision-making and cost-effectiveness analyses. Identified challenges impeding RWD integration into HTA encompassed limited local data access, complexities in non-randomized trial design, data quality, privacy, and fragmentation. Addressing these is imperative for optimal RWD utilization. Incorporating RWD/RWE in HTA yields multifaceted advantages, enhancing understanding of treatment efficacy, resource utilization, and cost analysis, particularly via patient registries. RWE complements assessments of advanced therapy medicinal products (ATMPs) and rare diseases. Local data utilization strengthens HTA, bridging gaps when RCT data is lacking. RWD aids medical device decision-making, cancer drug reassessment, and indirect treatment comparisons. Challenges include data availability, stakeholder acceptance, expertise, and privacy. However, standardization, training, collaboration, and guidance can surmount these barriers, fostering enhanced RWD utilization in HTA. Conclusion: This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.

Unlocking the Power of Real-World Data: A Framework for Sustainable Healthcare

An overview of Real-World Data infrastructure for cancer research

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network

Toward a Better Understanding about Real-World Evidence

Raising the Impact of Real World Evidence

Generating and using real-world data: A worthwhile uphill battle

Implementation and relevance of FAIR data principles in biopharmaceutical R&D

Improving Research Patient Data Repositories from a Health Data Industry Viewpoint (Preprint)

Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals

Harnessing electronic health records for real-world evidence

A Framework to Support the Standardized Management of Real-World Data

Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Real-world data: a brief review of the methods, applications, challenges and opportunities

A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making

Unlocking biomedical data sharing: A structured approach with digital twins and artificial intelligence (AI) for open health sciences

Real-World Evidence: A Primer

FAIR data sharing: An international perspective on why medical researchers are lagging behind

Applying FAIRness: Redesigning a Biomedical Informatics Research Data Management Pipeline

Electronic medical records as a source of real-world clinical data